Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on March 9, 2026, regarding events occurring on March 6, 2026. The filing reports the presentation of long-term follow-up data from the Company's nPulse™ Vybrance™ Percutaneous Electrode System first-in-human feasibility study at the North American Society for Interventional Thyroidology 2026 meeting in Portland, Oregon.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical study results and does not contain financial statements or operational financial data.
Material Changes and Clinical Findings
The primary material event is the announcement of clinical durability data for the treatment of benign thyroid nodules. Key findings from the 15-22 month follow-up of 21 patients include:
- Average 74% volume reduction of treated benign thyroid nodules.
- Continued volume reduction improvements observed from 1 month through 22 months.
- No regrowth of nodules detected at the 15-22 month mark.
- 100% of patients reported being "Highly Satisfied" with cosmetic outcomes.
- 95% of patients reported being "Highly Satisfied" with overall outcomes.
- No serious adverse events were reported.
- No intranodular fibrosis was detected on ultrasounds.
Outlook, Risks, and Management Commentary
Management highlights the potential for clinical durability of benign thyroid ablation using the nPulse Vybrance system. The data supports the continued efficacy and safety profile of the device over an extended period. No specific financial guidance, risks, or contingencies were disclosed in this filing.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for complete clinical data tables.
- Confirm the regulatory status of the nPulse Vybrance system for commercial use in the relevant markets.
- Review the Company's most recent 10-K or 10-Q for current financial health, cash runway, and debt obligations, as this 8-K contains no financial metrics.
- Assess the timeline for potential regulatory submissions or commercialization based on these durability results.